Drug Profile
Meplazumab - Pacific Meinuoke Bio Pharmaceutical
Alternative Names: Anti-CD147 humanized meplazumab; humanized mAb against CD147; KetantinLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Fourth Military Medical University
- Developer Fourth Military Medical University; Pacific Meinuoke Biopharmaceutical
- Class Antimalarials; Antivirals; Monoclonal antibodies
- Mechanism of Action Metalloprotease inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- No development reported Malaria
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Malaria in China (IV, Infusion)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Malaria(Prevention) in China (IV, Infusion)
- 06 Oct 2023 Pacific Meinuoke Bio Pharmaceutical withdraws a phase I trial prior to enrolment for Malaria (Prevention) (IV) due to the reason that same drug has completed the phase I and II clinical trials for COVID-19 (NCT04327310)